Genomic testing in identifying patients with DCIS likely to respond to radiotherapy

Wendy Taylor, MBBS, and Abigail Gault, MBBS, MRCP, PGCert, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, discuss recent advances in genomic testing, highlighting its potential role in ductal carcinoma in situ (DCIS) in identifying patients likely to respond to radiotherapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.